Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated alcohol-related liver disease represent distinct clinical phenotypes and fibrosis risk: insights from a population-based Polish cohort.

Polish archives of internal medicine·2026
Same author

Prevalence of hearing loss and other ear disorders among patients with hepatitis B infection: a nationwide retrospective Polish cohort study.

Scientific reports·2026
Same author

Recommendations for hypolipidemic and antithrombotic therapy in HCV-infected patients treated with direct-acting antiviral agents: expert position statement.

Clinical and experimental hepatology·2026
Same author

First documented case of Zika virus infection in a Polish patient - diagnostic traps. Case report.

Annals of agricultural and environmental medicine : AAEM·2026
Same author

Clinical characteristics of hospitalized patients with hepatitis E virus infection in Poland: a multi-centre retrospective study.

Advances in medical sciences·2026
Same author

Guidelines of the Polish Society of Gynecologists and Obstetricians on the management of girls and women subjected to sexual violence.

Ginekologia polska·2025

Related Experiment Video

Updated: May 8, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

A pill for HCV - myth or foreseeable future?

Jerzy Jaroszewicz1, Robert Flisiak, Geoffrey Dusheiko

  • 1Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland.

Liver International : Official Journal of the International Association for the Study of the Liver
|September 4, 2013
PubMed
Summary
This summary is machine-generated.

New all-oral, interferon-free therapies offer hope for treating chronic hepatitis C (HCV). While current treatments have limitations, these novel regimens show promise for difficult-to-treat patient populations.

Keywords:
HCVIFN freeIFN sparingchronic hepatitis Cdirect-acting agentsinterferon

More Related Videos

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors
16:49

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

Related Experiment Videos

Last Updated: May 8, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors
16:49

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Current standard of care for chronic hepatitis C (HCV) involves pegylated-interferon alfa (PegIFN) and ribavirin (RBV), achieving sustained virological response (SVR) rates of 40-50% for genotypes 1 or 4, and 70-90% for genotypes 2-3.
  • First-generation protease inhibitor triple therapy increases SVR to 75% for HCV genotype 1 but has limitations including dosing, complexity, side effects, and reduced efficacy in non-responders.
  • There is a significant unmet need for effective therapies in patients intolerant to PegIFN, particularly those with cirrhosis or prior treatment failures.

Purpose of the Study:

  • To review the progress and potential of all-oral, interferon-free therapies for chronic hepatitis C.
  • To assess the current landscape of HCV treatment, including limitations of existing regimens and the emergence of new oral therapies.

Main Methods:

  • Review of recent clinical trial data and submitted drug registrations for all-oral anti-HCV therapies.
  • Analysis of treatment outcomes and limitations associated with current and emerging HCV treatment strategies.

Main Results:

  • Initial results from clinical studies of all-oral, interferon-free therapies are promising for selected chronic hepatitis C populations.
  • The first all-oral combination therapy has been submitted for registration, indicating a significant advancement.
  • Challenges remain in defining the optimal role of interferon-free therapies for treatment-naïve patients and complex non-responders.

Conclusions:

  • All-oral, interferon-free therapies represent a significant evolutionary step in the management of chronic hepatitis C.
  • These novel regimens offer hope for improved treatment outcomes, especially for patients with difficult-to-treat conditions.
  • Further research and clinical trials are needed to establish clear treatment guidelines for interferon-free therapies in diverse patient populations.